Report
Pharma Mar : Q4 EBITDA and bottom line somewhat better albeit negative
>Higher royalties offset the anticipated oncology slowdown - Total revenues receded significantly -20% y-o-y in Q4 2023 (vs -9% in Q3 and -1% in Q2), yet they were above our estimate helped by higher-than-expected royalties and licences (€ 29m vs € 20m est.). Biopharma sales decreased -32% y-o-y in Q4 2023 (compared to -27% in Q3 and -2% in Q2) reflecting a normalisation after the inflated figures seen in previous quarters that were favoured by one-off ‘early-access...
Underlying
Pharma Mar SA
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Juan Ros-Padilla
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.